- Home
- BWB vs ALDX Comparison
BWB vs ALDX Comparison
Compare BWB & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWB
- ALDX
- Stock Information
- Founded
- BWB 2005
- ALDX 2004
- Country
- BWB United States
- ALDX United States
- Employees
- BWB N/A
- ALDX N/A
- Industry
- BWB Major Banks
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- BWB Finance
- ALDX Health Care
- Exchange
- BWB Nasdaq
- ALDX Nasdaq
- Market Cap
- BWB 365.0M
- ALDX 304.9M
- IPO Year
- BWB 2018
- ALDX 2014
- Fundamental
- Price
- BWB $13.76
- ALDX $6.81
- Analyst Decision
- BWB Strong Buy
- ALDX Strong Buy
- Analyst Count
- BWB 2
- ALDX 2
- Target Price
- BWB $17.50
- ALDX $10.00
- AVG Volume (30 Days)
- BWB 44.9K
- ALDX 592.8K
- Earning Date
- BWB 04-23-2025
- ALDX 05-01-2025
- Dividend Yield
- BWB N/A
- ALDX N/A
- EPS Growth
- BWB N/A
- ALDX N/A
- EPS
- BWB 1.03
- ALDX N/A
- Revenue
- BWB $106,036,000.00
- ALDX N/A
- Revenue This Year
- BWB $26.46
- ALDX N/A
- Revenue Next Year
- BWB $12.13
- ALDX N/A
- P/E Ratio
- BWB $13.48
- ALDX N/A
- Revenue Growth
- BWB N/A
- ALDX N/A
- 52 Week Low
- BWB $10.52
- ALDX $2.71
- 52 Week High
- BWB $16.00
- ALDX $7.19
- Technical
- Relative Strength Index (RSI)
- BWB 45.62
- ALDX 64.08
- Support Level
- BWB $13.52
- ALDX $4.78
- Resistance Level
- BWB $14.21
- ALDX $6.52
- Average True Range (ATR)
- BWB 0.32
- ALDX 0.55
- MACD
- BWB -0.08
- ALDX 0.03
- Stochastic Oscillator
- BWB 31.44
- ALDX 91.48
About BWB Bridgewater Bancshares Inc.
Bridgewater Bancshares Inc offers retail and commercial loan and deposit services to customers within the Minneapolis-St. Paul-Bloomington, MN-WI Metropolitan Statistical Area. The company engages in providing a wide range of deposit and lending products. Its products and services include commercial deposits, loans, online business services, credit card, mobile banking, and remote deposit services.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.